{
    "root": "b9cfbc86-86a5-487f-8b6d-1e9607d2f8f7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Maraviroc"
    },
    "value": "20250515",
    "ingredients": [
        {
            "name": "MARAVIROC",
            "code": "MD6P741W8A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A",
            "code": "H8AV0SQX4D"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        }
    ],
    "indications": "maraviroc tablets indicated combination antiretroviral agents treatment ccr5-tropic human immunodeficiency virus type 1 ( hiv-1 ) infection adult pediatric patients 2 years age older weighing least 10 kg . limitations : maraviroc tablets recommended patients dual/mixed- cxcr4-tropic hiv-1 [ microbiology ( 12.4 ) ] .",
    "contraindications": "prior initiation maraviroc tablets treatment hiv-1 infection , test patients ccr5 tropism using highly sensitive tropism assay . ( 2.1 ) maraviroc tablets taken twice daily mouth may taken without food . maraviroc tablets must given combination antiretroviral medications . ( 2.2 ) recommended adult patients : ( 2.3 ) concomitant medications maraviroc tablets given potent cytochrome p450 ( cyp ) 3a inhibitors ( without potent cyp3a inducers ) including pis ( except tipranavir/ritonavir ) ( 2.3 , 7.1 ) 150 mg twice daily nrtis , tipranavir/ritonavir , nevirapine , raltegravir , drugs potent cyp3a inhibitors cyp3a inducers ( 2.3 , 7.1 ) 300 mg twice daily potent moderate cyp3a inducers including efavirenz ( without potent cyp3a inhibitor ) ( 2.3 , 7.1 ) 600 mg twice daily complete list coadministered drugs listed . ( 2 ) recommended pediatric patients 2 years older weighing least 10 kg : administer twice daily . based body weight ( kg ) concomitant medications exceed recommended adult dose . ( 2.4 ) recommended patients renal impairment : dose adjustment may necessary adult patients renal impairment . ( 2.5 )",
    "warningsAndPrecautions": "maraviroc film-coated tablets available follows : 150-mg white off-white color , oval , biconvex , film-coated tablet debossed `` nav `` `` 125 `` one side plain side . bottle 60 tablets ( ndc 70710-1930-6 ) 300-mg white off-white color , oval , biconvex , film-coated tablet debossed `` nav `` `` 124 `` one side plain side . bottle 60 tablets ( ndc 70710-1931-6 ) maraviroc film-coated tablets stored 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "maraviroc tablets contraindicated patients severe renal impairment esrd ( crcl less 30 ml per minute ) concomitantly taking potent cyp3a inhibitors inducers [ ( 5.3 ) ] .",
    "indications_original": "Maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg.\n                  Limitations of Use:\n                  \n                     Maraviroc tablets are not recommended in      patients with dual/mixed- or CXCR4-tropic HIV-1 [see Microbiology (12.4)].",
    "contraindications_original": "Prior to initiation of maraviroc tablets for treatment of HIV-1 infection, test all patients for CCR5 tropism using a highly sensitive tropism assay. ( 2.1 ) Maraviroc tablets are taken twice daily by mouth and may be taken with or without food. Maraviroc tablets must be given in combination with other antiretroviral medications. ( 2.2 ) Recommended Dosage in Adult Patients: ( 2.3 ) Concomitant Medications Dosage of Maraviroc tablets When given with potent cytochrome P450 (CYP)3A inhibitors (with or without potent CYP3A inducers) including PIs (except tipranavir/ritonavir) ( 2.3 , 7.1 ) 150 mg twice daily With NRTIs, tipranavir/ritonavir, nevirapine, raltegravir, and other drugs that are not potent CYP3A inhibitors or CYP3A inducers ( 2.3 , 7.1 ) 300 mg twice daily With potent and moderate CYP3A inducers including efavirenz (without a potent CYP3A inhibitor) (2.3 , 7.1 ) 600 mg twice daily A more complete list of coadministered drugs is listed in Dosage and Administration . ( 2 ) Recommended Dosage in Pediatric Patients 2 years and older and weighing at Least 10 kg: Administer twice daily. Dosage should be based on body weight (kg) and concomitant medications and should not exceed the recommended adult dose. ( 2.4 ) Recommended Dosage in Patients with Renal Impairment: Dose adjustment may be necessary in adult patients with renal impairment. ( 2.5 )",
    "warningsAndPrecautions_original": "Maraviroc film-coated tablets are available as follows:\n                  150-mg white to off-white color, oval, biconvex, film-coated tablet debossed with \"NAV\" and \"125\" one side and plain on the other side.\n                  Bottle of 60 tablets (NDC 70710-1930-6)\n                  300-mg white to off-white color, oval, biconvex, film-coated tablet debossed with \"NAV\" and \"124\" one side and plain on the other side.\n                  Bottle of 60 tablets (NDC 70710-1931-6)\n                  Maraviroc film-coated tablets should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Maraviroc tablets are contraindicated in patients with severe renal impairment or ESRD (CrCl less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers [see Warnings and Precautions (5.3)]."
}